The Impact of Interferon Beta 1a on Egyptian Relapse-Remitting Multiple Sclerosis Patients
Sponsored by German University in Cairo
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 2 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Age between 18 and 50 years at time of signing informed consent form.
- Relapsing- remitting multiple sclerosis as per the McDonald 2017 criteria, including an MRI brain satisfying the 2017 radiological criteria.
- Full-field visual evoked potential (VEP) P100 latency in at least one eye of ≥118 ms.
- Kurtzke EDSS step 0.0 - 6.0.
- At the time of screening, being treated with a stable dose for at least 6 months of a category 1 multiple sclerosis DMT or for at least 2 years with a category 2 DMT.
Exclusion Criteria
- they had been treated in the last 30 days with methylprednisolone
- they had changed their IFN-β preparation within the last 18 months
- they had other chronic diseases associated with MS
- they had been previously treated with immunosuppressive agents